Literature DB >> 10096508

Synthesis and evaluation of 6-[11C]methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2- benzisoxazole as an in vivo radioligand for acetylcholinesterase.

C Brown-Proctor1, S E Snyder, P S Sherman, M R Kilbourn.   

Abstract

6-Methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzisoxazole is a high affinity (K(i) = 8.2 nM) reversible inhibitor of acetylcholinesterase (AChE). The carbon-11 labeled form was prepared in high (>97%) radiochemical purity and with specific activities of 37+/-20 GBq/micromol at end of synthesis, by the alkylation of the desmethyl precursor with [11C]methyl trifluoromethanesulfonate in N,N-dimethyl-formamide at room temperature. In vivo studies in mice demonstrated good blood brain permeability but essentially uniform regional brain distribution. Thus, despite in vitro and in vivo activity as an AChE inhibitor, 6-[11C]methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2-benzis oxa zole does not appear to be a good candidate for in vivo imaging studies of AChE in the mammalian brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096508     DOI: 10.1016/s0969-8051(98)00078-x

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  3 in total

1.  5-tert-Butyl-2-(4'-[18F]fluoropropynylphenyl)-1,3-dithiane oxides: potential new GABA A receptor radioligands.

Authors:  Xuehe Li; Yong-Woon Jung; Scott E Snyder; Joseph Blair; Philip S Sherman; Timothy Desmond; Kirk A Frey; Michael R Kilbourn
Journal:  Nucl Med Biol       Date:  2007-11-26       Impact factor: 2.408

2.  Synthesis of novel 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole derivatives as antiproliferative agents: a structure-activity relationship study.

Authors:  S B Benaka Prasad; K Vinaya; C S Ananda Kumar; Sanjay Swarup; K S Rangappa
Journal:  Invest New Drugs       Date:  2008-12-06       Impact factor: 3.850

Review 3.  Benzisoxazole: a privileged scaffold for medicinal chemistry.

Authors:  K P Rakesh; C S Shantharam; M B Sridhara; H M Manukumar; Hua-Li Qin
Journal:  Medchemcomm       Date:  2017-10-31       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.